StreetInsider.com News Articles

Form SCHEDULE 13G Jasper Therapeutics, Filed by: INTEGRATED CORE STRATEGIES (US) LLC

Wed, 25 Feb 2026 16:47:00 -0500

si-local-file:///var/storage/secattach/20260225/26061135.html

Form SCHEDULE 13G Jasper Therapeutics, Filed by: INTEGRATED CORE STRATEGIES (US) LLC

Wed, 25 Feb 2026 16:47:00 -0500

si-local-file:///var/storage/secattach/20260225/26061135.html

Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference

Tue, 24 Feb 2026 16:30:00 -0500

REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that management will participate at the 46th Annual TD Cowen Healthcare Conference, taking place March 2-4, 2026 in Boston, MA.

46th Annual TD Cowen Healthcare Conference
Conference Dates: March 2-4, 2026
Presentation Date/Time: Monday, March 2, 2026; 3:50 PM EST
Presentation Format: Fireside Chat

A live webcast of the

Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference

Tue, 24 Feb 2026 16:30:00 -0500

46th Annual TD Cowen Healthcare Conference
Conference Dates: March 2-4, 2026
Presentation Date/Time: Monday, March 2, 2026; 3:50 PM EST
Presentation Format: Fireside Chat

A live webcast of the

Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference

Tue, 24 Feb 2026 16:30:00 -0500

46th Annual TD Cowen Healthcare Conference
Conference Dates: March 2-4, 2026
Presentation Date/Time: Monday, March 2, 2026; 3:50 PM EST
Presentation Format: Fireside Chat

A live webcast of the

Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference

Tue, 24 Feb 2026 16:30:00 -0500

46th Annual TD Cowen Healthcare Conference
Conference Dates: March 2-4, 2026
Presentation Date/Time: Monday, March 2, 2026; 3:50 PM EST
Presentation Format: Fireside Chat

A live webcast of the

Form SCHEDULE 13D/A Jasper Therapeutics, Filed by: Carlyle Group Inc.

Wed, 18 Feb 2026 17:29:00 -0500

si-local-file:///var/storage/secattach/20260218/26023768.html

Form SCHEDULE 13D/A Jasper Therapeutics, Filed by: Carlyle Group Inc.

Wed, 18 Feb 2026 17:29:00 -0500

si-local-file:///var/storage/secattach/20260218/26023768.html

Form SCHEDULE 13G Jasper Therapeutics, Filed by: GOLDMAN SACHS GROUP INC

Thu, 12 Feb 2026 10:33:00 -0500

si-local-file:///var/storage/secattach/20260212/25989311.html

Form SCHEDULE 13G Jasper Therapeutics, Filed by: GOLDMAN SACHS GROUP INC

Thu, 12 Feb 2026 10:33:00 -0500

si-local-file:///var/storage/secattach/20260212/25989311.html

Form SCHEDULE 13G Jasper Therapeutics, Filed by: MORGAN STANLEY

Wed, 11 Feb 2026 13:39:00 -0500

si-local-file:///var/storage/secattach/20260211/25982276.html

Form SCHEDULE 13G Jasper Therapeutics, Filed by: MORGAN STANLEY

Wed, 11 Feb 2026 13:39:00 -0500

si-local-file:///var/storage/secattach/20260211/25982276.html

Form 4 Jasper Therapeutics, For: Feb 06 Filed by: Mahal Jeetinder Singh

Tue, 10 Feb 2026 16:01:00 -0500

si-local-file:///var/storage/secattach/20260210/25975345.html

Form 4 Jasper Therapeutics, For: Feb 06 Filed by: Mahal Jeetinder Singh

Tue, 10 Feb 2026 16:01:00 -0500

si-local-file:///var/storage/secattach/20260210/25975345.html

Form SCHEDULE 13G/A Jasper Therapeutics, Filed by: ACORN BIOVENTURES, L.P.

Mon, 26 Jan 2026 15:29:00 -0500

si-local-file:///var/storage/secattach/20260126/25893049.html

Form SCHEDULE 13G/A Jasper Therapeutics, Filed by: ACORN BIOVENTURES, L.P.

Mon, 26 Jan 2026 15:29:00 -0500

si-local-file:///var/storage/secattach/20260126/25893049.html

Rodman & Renshaw Starts Jasper Therapeutics (JSPR) at Buy

Tue, 13 Jan 2026 07:19:03 -0500

(Updated - January 13, 2026 7:19 AM EST)

Rodman & Renshaw analyst Michael King Jr. initiates coverage on Jasper Therapeutics (NASDAQ: JSPR) with a Buy rating and a price target of $17.00.

The analyst comments "We are initiating coverage of Jasper Therapeutics (JSPR) with a Buy rating and 12-month price target of $17 based on a sum-of-the-parts valuation framework reflecting briquilimab’s compelling efficacy profile in mast cell-driven diseases, renewed clinical advancement, and substantial market opportunity across multiple indications. Jasper Therapeutics represents a unique opportunity to invest in a company with a potential best-in-class product profile targeting one of immunology's most fundamental yet

Rodman & Renshaw Starts Jasper Therapeutics (JSPR) at Buy

Tue, 13 Jan 2026 07:19:03 -0500

(Updated - January 13, 2026 7:19 AM EST)

Rodman & Renshaw analyst Michael King Jr. initiates coverage on Jasper Therapeutics (NASDAQ: JSPR) with a Buy rating and a price target of $17.00.

Jasper Therapeutics (JSPR) Reiterated at Market Outperform by Citizens

Fri, 09 Jan 2026 04:33:48 -0500

Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $6.00 price target on Jasper Therapeutics (NASDAQ: JSPR).

The analyst commented, "We believe briquilimab is differentiated, but a financing overhang is holding back the stock. Jasper Therapeutics reported updated data from the BEACON CSU study, and open-label expansion cohort, demonstrating efficacy consistent with prior results—after correcting enrollment issues from a new site— and enrolling new patients. Jasper appointed Jeet Mahal as CEO to lead the company into its planned Phase 2b study, a milestone that will require additional funding that new leadership is expected to help secure. We maintain our Market

Form 8-K Jasper Therapeutics, For: Jan 08

Thu, 08 Jan 2026 07:07:00 -0500

si-local-file:///var/storage/secattach/20260108/25822946.html

Form 8-K Jasper Therapeutics, For: Jan 08

Thu, 08 Jan 2026 07:07:00 -0500

si-local-file:///var/storage/secattach/20260108/25822946.html

Jasper Therapeutics reports positive briquilimab data for urticaria treatment

Thu, 08 Jan 2026 07:03:42 -0500

Jasper Therapeutics Inc. (NASDAQ: JSPR) reported clinical trial data showing its drug candidate briquilimab achieved disease control in patients with chronic spontaneous urticaria.

In the BEACON Phase 1b/2a study, 67% of six additional patients who received briquilimab achieved complete response at 12 weeks, with a mean reduction of 31 points on the Urticaria Activity Score over 7 days (UAS7). The study evaluates subcutaneous briquilimab in adults with moderate to severe chronic spontaneous urticaria despite high-dose antihistamine treatment.

In the open-label extension study using a 180mg dose every 8 weeks, 58% of 36 chronic spontaneous urticaria patients achieved complete response at 12 weeks,

Jasper Therapeutics reports positive briquilimab data for urticaria treatment

Thu, 08 Jan 2026 07:03:42 -0500

Jasper Therapeutics Inc. (NASDAQ: JSPR) reported clinical trial data showing its drug candidate briquilimab achieved disease control in patients with chronic spontaneous urticaria.

In the open-label extension study using a 180mg dose every 8 weeks, 58% of 36 chronic spontaneous urticaria patients achieved complete response at 12 weeks,

Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria

Thu, 08 Jan 2026 07:00:00 -0500

67% of additional patients (n=6) enrolled in the BEACON study achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points

75% of CSU participants (n=36) enrolled in the open label extension study achieved a complete response or well controlled disease at 12 weeks

With a median duration of follow up of more than 200 days on 63 participants in the open label extension study, KIT related AEs were low in frequency and predominantly low-grade events that resolved while on study

BEACON and open label extension data sets are

Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria

Thu, 08 Jan 2026 07:00:00 -0500

67% of additional patients (n=6) enrolled in the BEACON study achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points

75% of CSU participants (n=36) enrolled in the open label extension study achieved a complete response or well controlled disease at 12 weeks

With a median duration of follow up of more than 200 days on 63 participants in the open label extension study, KIT related AEs were low in frequency and predominantly low-grade events that resolved while on study

BEACON and open label extension data sets are